Hoffmann-La Roche Inc.

Syntex (u.s.a.) Inc.

F. Hoffmann-La Roche Ag

Guido Galley

Roger David Norcross

Katrin Groebke Zbinden

Philippe Pflieger

Henri Stalder

Annick Goergler

Thierry Godel

Torsten Hoffmann

Patrick Schnider

Heinz Stadler

Walter Hunkeler

Michael B&ouml;s

Giuseppe Cecere

Roland Jakob-Roetne

Eric Argirios Kitas

Jens-Uwe Peters

Alexander Flohr

Marius Hoener

Hasane Ratni

Werner Neidhart

Sabine Kolczewski

Wolfgang Wostl

Hong Shen

Anja Limberg

Bjoern Bartels

Yimin Hu

Rosa Maria Rodriguez Sarmiento

Geo Adam

Quirico Branca

Andrea Cesura

Stephan Rover

Jurgen Wichmann

Karlheinz Baumann

Angelique Patiny-Adam

Francedillaois Jenck

Cedric Ghellamallah

Georg Jaeschke

Michael Patrick Dillon

Stephan Roever

Daniel Hunziker

Luca Claudio Gobbi

Wolfgang Guba

Robert Alan Goodnow, Jr

Rosa Maria Rodriguez-Sarmiento

Michael Reutlinger

Andreas Koblet

Valerie Runtz-Schmitt

Christian Schnider

Maria-Clemencia Hernandez

Daniela Krummenacher

Philipp Schmid

Helmut Jacobsen

Alessandra Polara

Angélique Patiny-Adam

Nicolas Zorn

Andrés Miguel Olivares Morales

Stefan Berchtold

Björn Bartels

Etienne Rauber

Alina Tirla

Dawn Muszynski Barsy

Hai-Ying Cai

Reinhard Heck

Frederick Monsma, Jr

The invention relates to a compound of formula (I), wherein R-Rand A-Aare as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

CGAS inhibiting triazolopyrimidone derivatives

The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.

Benzodiazepine derivatives as GABA A gamma 1 PAM

The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein Ris hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, if two Roccur; Ris lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH-heterocycloalkyl unsubstituted or substituted by lower alkyl; Ris halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(O)-lower alkyl; n is 1, 2 or 3; if n is &#x3e;1, then Rmay be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. 

Phenoxytriazoles

The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.

Morpholine derivative

The present invention relates to compounds of formula  The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

Bridged piperidine derivatives

The present invention relates to a compound of formula wherein The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors. 

Dimeric compounds

The present invention relates to compounds of formula of formula I wherein R, R, Rand L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I. 

Substituted pyrazino[2,2-a]isoquinoline derivatives

The present invention relates to compounds of formula of formula I wherein R, R. R, R, R, R, R, L, Land N are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I. 

Substituted azetidine derivatives

The present invention relates to compounds TAAR receptor antagonists of formula I wherein X, R, L, Ar and Rare as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric disorders with compounds of formula I. 

6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives

The present invention relates to compounds of formula of formula I wherein X, R, L, Ar, Rand n are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric disorders with compounds of formula I. 

Morpholin-pyridine derivatives

The present invention relates to compounds of formula of formula I wherein X, L and Rare as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I. 

2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives

The present invention relates to compounds of formula of formula I wherein X, Ar, R, m and n are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric disorders with compounds of formula I. 

5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives

Growing community of inventors

Rheinfelden, Germany

Guido Galley